NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free INO Stock Alerts $8.92 -0.17 (-1.87%) (As of 04:02 PM ET) Add Compare Share Share Today's Range$8.76▼$9.1050-Day Range$9.09▼$13.0752-Week Range$3.89▼$14.75Volume204,756 shsAverage Volume443,727 shsMarket Capitalization$231.12 millionP/E RatioN/ADividend YieldN/APrice Target$70.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Inovio Pharmaceuticals alerts: Email Address Inovio Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside689.6% Upside$70.67 Price TargetShort InterestHealthy7.28% of Float Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.50) to ($3.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector208th out of 913 stocksSurgical & Medical Instruments Industry30th out of 99 stocks 3.4 Analyst's Opinion Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInovio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Inovio Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.28% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 12.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInovio Pharmaceuticals has received a 73.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inovio Pharmaceuticals is -0.74. Previous Next 3.0 News and Social Media Coverage News SentimentInovio Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inovio Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest17 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.50) to ($3.16) per share.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Inovio Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academyonly trade options on these 5-7 stocksI'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing special about these stocks. What matters is the repeatable options trading system I use to trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Inovio Pharmaceuticals Stock (NASDAQ:INO)Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.Read More INO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INO Stock News HeadlinesJune 4, 2024 | prnewswire.comINOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.May 31, 2024 | prnewswire.comINOVIO Reports Inducement Grants Under Inducement PlanMay 29, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Anal Cancer Market to Showcase Growth at a CAGR of 18% by 2034 | DelveInsightMay 29, 2024 | finance.yahoo.comAnal Cancer Market to Showcase Growth at a CAGR of 18% by 2034 | DelveInsightMay 22, 2024 | fool.comBetter Buy: Inovio Pharmaceuticals vs. NovavaxMay 18, 2024 | msn.comINOVIO Reports First Quarter Financials, Prepares for Major Drug SubmissionsMay 15, 2024 | finanznachrichten.deINOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Inovio Pharmaceuticals (INO) with Overweight RecommendationMay 14, 2024 | markets.businessinsider.comDNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: AnalystMay 14, 2024 | markets.businessinsider.comInovio Pharmaceuticals: Hold Rating Amidst Clinical Progress and Financial CautionMay 14, 2024 | insidermonkey.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comInovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | investorplace.comINO Stock Earnings: Inovio Pharmaceuticals Misses EPS for Q1 2024May 13, 2024 | nasdaq.comInovio Pharmaceuticals Inc. Q1 Loss DeclinesMay 13, 2024 | sfgate.comInovio: Q1 Earnings SnapshotMay 13, 2024 | prnewswire.comINOVIO Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 12, 2024 | msn.comInovio Pharmaceuticals Q1 2024 Earnings PreviewMay 12, 2024 | markets.businessinsider.comInovio Pharmaceuticals earnings: here's what Wall Street expectsMay 6, 2024 | msn.comINOVIO Awards Equity Grants to New Employees Under 2022 Inducement PlanMay 5, 2024 | fool.comThis Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?May 1, 2024 | prnewswire.comINOVIO Reports Inducement Grants Under Inducement PlanApril 29, 2024 | prnewswire.comINOVIO to Report First Quarter 2024 Financial Results on May 13, 2024April 29, 2024 | prnewswire.comINOVIO to Participate in Upcoming Investor Conferences in MayApril 25, 2024 | finance.yahoo.comPharmaJet’s needle-free delivery system proves effective in published studyApril 25, 2024 | seekingalpha.comInovio Pharmaceuticals: The Dilution ContinuesSee More Headlines Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:INO CUSIPN/A CIK1055726 Webwww.inovio.com Phone(267) 440-4200Fax267-440-4242Employees122Year Founded1979Price Target and Rating Average Stock Price Target$70.67 High Stock Price Target$144.00 Low Stock Price Target$20.00 Potential Upside/Downside+692.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,120,000.00 Net Margins-16,238.91% Pretax Margin-17,423.72% Return on Equity-88.13% Return on Assets-63.03% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.77 Sales & Book Value Annual Sales$830,000.00 Price / Sales278.45 Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book1.73Miscellaneous Outstanding Shares25,910,000Free Float25,263,000Market Cap$231.12 million OptionableOptionable Beta0.99 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jacqueline E. Shea Ph.D. (Age 58)CEO, President & Director Comp: $1.13MMr. Peter D. Kies (Age 61)Chief Financial Officer Comp: $810.2kDr. Laurent M. Humeau Ph.D. (Age 57)Chief Scientific Officer Comp: $794.08kThomas HongManager of Investor RelationsMr. Robert L. Crotty J.D. (Age 50)General Counsel & Chief Compliance Officer Mr. E. J. Brandreth MBASenior Vice President of Quality AssuranceDr. Jeffrey SkolnikSenior Vice President of Clinical DevelopmentMr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply ManagementMr. Stephen Kemmerrer M.B.A.P.E., Senior Vice President of Engineering DevelopmentMr. Shawn D. Bridy M.A.M.B.A., Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsArtivionNYSE:AORTSilk Road MedicalNASDAQ:SILKPerspective TherapeuticsNYSE:CATXAtrionNASDAQ:ATRIPulse BiosciencesNASDAQ:PLSEView All CompetitorsInstitutional OwnershipJacobs Levy Equity Management Inc.Sold 1,133,477 shares on 5/16/2024Ownership: 0.071%Price T Rowe Associates Inc. MDSold 137,501 shares on 5/15/2024Ownership: 0.053%Vanguard Group Inc.Sold 18,171,677 shares on 5/10/2024Ownership: 6.822%Susquehanna Fundamental Investments LLCBought 106,791 shares on 5/7/2024Ownership: 0.457%GSA Capital Partners LLPSold 3,716,550 shares on 5/3/2024Ownership: 0.342%View All Institutional Transactions INO Stock Analysis - Frequently Asked Questions Should I buy or sell Inovio Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" INO shares. View INO analyst ratings or view top-rated stocks. What is Inovio Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued twelve-month price objectives for Inovio Pharmaceuticals' shares. Their INO share price targets range from $20.00 to $144.00. On average, they expect the company's stock price to reach $70.67 in the next twelve months. This suggests a possible upside of 689.6% from the stock's current price. View analysts price targets for INO or view top-rated stocks among Wall Street analysts. How have INO shares performed in 2024? Inovio Pharmaceuticals' stock was trading at $73.44 at the start of the year. Since then, INO shares have decreased by 87.8% and is now trading at $8.95. View the best growth stocks for 2024 here. Are investors shorting Inovio Pharmaceuticals? Inovio Pharmaceuticals saw a decline in short interest in May. As of May 31st, there was short interest totaling 1,870,000 shares, a decline of 12.6% from the May 15th total of 2,140,000 shares. Based on an average daily trading volume, of 384,600 shares, the days-to-cover ratio is presently 4.9 days. Currently, 7.3% of the company's stock are sold short. View Inovio Pharmaceuticals' Short Interest. When is Inovio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our INO earnings forecast. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Monday, May, 13th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by $0.23. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 88.13% and a negative net margin of 16,238.91%. During the same quarter in the previous year, the business posted ($1.92) earnings per share. What ETF holds Inovio Pharmaceuticals' stock? Amplify Treatments, Testing and Advancements ETF holds 4,891 shares of INO stock, representing 0.48% of its portfolio. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals shares reverse split on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO? 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.82%), Susquehanna Fundamental Investments LLC (0.46%), GSA Capital Partners LLP (0.34%), Green Alpha Advisors LLC (0.16%), Simplex Trading LLC (0.00%) and Jacobs Levy Equity Management Inc. (0.07%). Insiders that own company stock include David B Weiner and Simon X Benito. View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INO) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.